AbbVie’s Q3 2026 Playbook: Immunology Momentum, Apogee Onboard, and a Dividend Nudge

Ticker ABBV, EPS numbers in focus: GAAP EPS of $2.37 and Adjusted EPS of $3.82 for the quarter on $17.404 billion in net revenues. The release is rich in portfolio detail, highlights a completed acquisition (Apogee Therapeutics), and raises the revenue forecast through higher 2026 EPS guidance — all while noting the inevitable IPR&D drag. If you track EPS consensus figures, be aware this press release doesn’t publish a straight-ahead consensus number in the document itself, leaving the street to adjudicate relative to others’ estimates.

Key Q3 2026 figures at a glance

Ticker: ABBV (NYSE)
Net revenues: $17.404 billion, up 10.3% on a reported basis and 10.5% on an operational basis
GAAP EPS: $2.37 for the quarter
Adjusted Diluted EPS: $3.82; includes an unfavourable $0.11 per share impact from acquired IPR&D and milestones expenses
Acquisition: Completion of Apogee Therapeutics transaction, expanding the immunology pipeline
Guidance: 2026 adjusted diluted EPS guidance raised to $13.95–$13.99 (includes a $0.69 per share IPR&D expense drag incurred year-to-date through Q3 2026)
Dividend: 2027 dividend increase of 5.2%, starting with February 2027 payment
Currency note: Comparisons presented at constant currency to reflect local-currency net revenues

Portfolio performance: where the money came from

The quarterly press release dissects revenues by major franchises, underscoring AbbVie’s reliance on a few high-velocity assets while continuing to bake in a growth plan across immunology, neuroscience, oncology, and aesthetics.

Immunology

Net revenues from the Immunology portfolio were led by Skyrizi at $5.776 billion and Rinvoq at $2.706 billion, with Humira contributing $683 million as it tapers from its dominant legacy position. The mix reinforces the company's pivot from Humira’s peak to an expanded immunology machine, aided by Apogee’s assets.

Neuroscience

Neuroscience delivered $1.068 billion from Vraylar and $1.080 billion from Botox Therapeutic. Ubrelvy and Qulipta together added about $847 million, while Vyalev produced roughly $286 million in net revenues for the quarter. The neuroscience line remains a meaningful, diversification-driven ballast.

Oncology

Oncology contributed $803 million from Venclexta, $522 million from Imbruvica, and $224 million from Elahere. The portfolio shows continued breadth, with near-term reliance still on established franchises while late-stage assets earn their keep.

Aesthetics

Aesthetics produced $669 million from Botox Cosmetic and $222 million from Juvederm. The segment’s trajectory is softer versus Immunology, illustrating how consumer-facing products face distinct demand cycles.

Apogee Therapeutics: pipeline expansion and its accounting drag

AbbVie flags the successful completion of the Apogee Therapeutics acquisition, signaling a deeper immunology pipeline and potential future contribution to top-line growth. Importantly, the company discloses an unfavourable $0.69 per share impact from acquired IPR&D and milestones expenses incurred year-to-date through Q3 2026. That drag is being absorbed in the 2026 EPS guidance uplift, illustrating how management trades current earnings clarity for longer-term pipeline optionality.

Outlook, strategy, and capital allocation

AbbVie raised its 2026 revenue forecast in the guise of higher Adjusted Diluted EPS guidance, now pegged at $13.95–$13.99. The move implies management fingerprints on continued operating momentum despite IPR&D headwinds tied to Apogee. The 5.2% dividend increase for 2027 signals a commitment to returning capital even as the company pivots away from Humira’s waning revenue.

Strategically, AbbVie’s path hinges on sustaining the Immunology engine (Skyrizi, Rinvoq) while the Apogee addition buffers the pipeline risk associated with Humira’s decline. The company’s diversification into Neuroscience and Oncology provides optionality, but execution will matter as the portfolio shifts from high-visibility blockbuster revenue to a broader, multi-asset growth profile.

What this portends for AbbVie and its peers

Portfolio breadth matters. A robust immunology backbone paired with a growing pipeline (via Apogee) reduces single-asset risk and may support multiple growth vectors in an environment of pricing pressure.
IPR&D accounting is real. The IPR&D and milestone expense drag is highlighted in the EPS guidance, reminding investors that acquisitions can swing both the near-term profits and the longer-term value proposition.
Capital returns remain a fixture. The dividend increase reinforces a conservative, shareholder-friendly capital-allocation stance that can support multiple tone goals—growth, durability, and investor confidence.
Peer implications. For sector peers, the aflevering (the blend of growth assets, pipeline refresh, and disciplined guidance) sets a benchmark for how to balance current earnings with pipeline optionality in a post-Humira world.

In Matt Levine fashion: AbbVie is almost running a living spreadsheet disguised as a pharma company—where the big line items are not just the drugs but the bets the company makes on a future where the immunology franchise remains the core, even as Apogee steps into the wings with potential late-stage drama and milestones. It’s not a single story; it’s a portfolio story with a dividend garnish and a few lines in the footnotes about IPR&D that remind you the math is never as clean as the chart makes it look.